Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Low dose HP-hMG in an antagonist protocol for IVF in ovulatory and anovulatory patients with high AMH

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The impact of gastric bypass surgery on sex hormones and menstrual cycles in premenopausal women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Left-right differences in ovarian volume and antral follicle count in 1423 women of reproductive age

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Sex-specific estrogen levels and reference intervals from infancy to late adulthood determined by LC-MS/MS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Ovarian reserve markers in women using various hormonal contraceptives

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ovarian cortical follicle density in infertile women with low anti-Müllerian hormone

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Corifollitropin, a long-acting follicle-stimulating hormone (FSH) analogue used for in vitro fertilization (IVF), does not allow individualization of dosage, and the ovarian response is similar to around 300 IU of daily recombinant FSH. This has raised concerns about the risk of ovarian hyperstimulation syndrome (OHSS) when used in standard patients. We administered corifollitropin selectively to patients with anticipated low to moderate ovarian response based on antimüllerian hormone levels in the lower quartile. The end points were oocyte distribution and occurrence of OHSS in women with AMH  ≤15 pmol/L. The study included a cohort of 368 patients treated in 599 cycles. Post hoc the cohort was subdivided according to AMH. With increasing baseline AMH, the number of oocytes increased from a mean of 2.7 (range 0-8 with AMH  <3 pmol/L) to 6.3 (range 0-15 with AMH 10-15 pmol/L) oocytes. Cancellations of retrievals and transfers decreased significantly with increasing AMH. Overall, the ongoing live pregnancy rate per started cycle was 15.2%. None developed OHSS. No cycles were cancelled or needed triggering of ovulation using a GnRH agonist due to risk of OHSS. Selective use of corifollitropin in patients with AMH in the lower quartile is a safe and appropriate way of optimising stimulation.

OriginalsprogEngelsk
TidsskriftGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Vol/bind32
Udgave nummer8
Sider (fra-til)625-28
DOI
StatusUdgivet - 18 feb. 2016

ID: 46525015